Daniel Estes
QuietNamed in filings at Frazier Life Sciences
- Board seats filed
- 7
all filings on record
Named in filings at Frazier Life Sciences
all filings on record
last 24 months
from a verified or cited source
| Bluejay Therapeutics | Biotech & pharma | May 2024 | None on file |
| Eyconis | Biotech & pharma | January 2024 | Venbio Global Strategic |
| Radionetics Oncology | Biotech & pharma | August 2023 | Excelerate Health Ventures |
| Sudo Biosciences | Biotech & pharma | April 2021 | None on file |
| Arcutis Biotherapeutics | Biotech & pharma | October 2019 | Bain Capital Life Sciences |
| Cirius Therapeutics | Biotech & pharma | March 2017 | None on file |
| Outpost Medicine | Biotech & pharma | March 2016 | TCG Crossover, Vivo Capital |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The category is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Categories of companies where filings name Daniel Estes on the board, based on 7 filed seats with a verified or cited source.